Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations

May Almukainzi, Ranih Gabr, Ghada Abdelhamid, Raimar Löbenberg

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The physiological parameters that describe the reasons behind metformin accumulation in renal failure patients are not fully understood. The effect of high creatinin level in these patients on the elimination of metformin is unknown. The objectives of this work were to (1) evaluate the utility of Physiologically based pharmacokinetic (PBPK) modeling to predict the plasma levels of metformin in healthy and renal impairment individuals (2) identify parameters that explain the observed plasma levels in renal impairment (3) investigate the correlation between creatinine levels and metformin elimination by MATE1 transporter assuming competitive inhibition on this transporter. All simulations were performed using a PBPK approach in GastroPlus™. The simulated data was compared to experimental data in healthy adults and renal failure patients, who received 850 mg metformin HCl. To investigate the effect of creatinin level on the elimination of metformin through MATE1 transporter, 0.35, 0.5, 1, 2, and 5 mg/dl of creatinine on the elimination of 10 µM metformin were investigated in human embryonic kidney (HEK293) and in MATE1 overexpressed HEK293 cell. Our model was able to predict metformin absorption in healthy and renal failure patients. The renal dysfunction model showed that a down-regulation of the MATE1 transporter in kidney and liver was necessary to explain the increase in drug concentration in these patients. However, the accumulation of creatinine in renal impairment patients could not be linked to the MATE1 down-regulation. Understanding the reasons for the increase in metformin blood concentrations can help in reducing the clinical studies and the side effects in these patients.

Original languageEnglish
Pages (from-to)151-161
Number of pages11
JournalJournal of Pharmaceutical Investigation
Volume47
Issue number2
DOIs
Publication statusPublished - 1 Mar 2017

Fingerprint

Computer Simulation
Kidney
Renal Insufficiency
Creatinine
Down-Regulation
Pharmacokinetics
HEK293 Cells
Liver

Keywords

  • Drug simulation
  • Gastroplus™
  • HEK293
  • MATE transporter
  • Metformin
  • PBPK modeling

Cite this

@article{922a6de07b354ebda2d2d1af5c62a462,
title = "Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations",
abstract = "The physiological parameters that describe the reasons behind metformin accumulation in renal failure patients are not fully understood. The effect of high creatinin level in these patients on the elimination of metformin is unknown. The objectives of this work were to (1) evaluate the utility of Physiologically based pharmacokinetic (PBPK) modeling to predict the plasma levels of metformin in healthy and renal impairment individuals (2) identify parameters that explain the observed plasma levels in renal impairment (3) investigate the correlation between creatinine levels and metformin elimination by MATE1 transporter assuming competitive inhibition on this transporter. All simulations were performed using a PBPK approach in GastroPlus™. The simulated data was compared to experimental data in healthy adults and renal failure patients, who received 850 mg metformin HCl. To investigate the effect of creatinin level on the elimination of metformin through MATE1 transporter, 0.35, 0.5, 1, 2, and 5 mg/dl of creatinine on the elimination of 10 µM metformin were investigated in human embryonic kidney (HEK293) and in MATE1 overexpressed HEK293 cell. Our model was able to predict metformin absorption in healthy and renal failure patients. The renal dysfunction model showed that a down-regulation of the MATE1 transporter in kidney and liver was necessary to explain the increase in drug concentration in these patients. However, the accumulation of creatinine in renal impairment patients could not be linked to the MATE1 down-regulation. Understanding the reasons for the increase in metformin blood concentrations can help in reducing the clinical studies and the side effects in these patients.",
keywords = "Drug simulation, Gastroplus™, HEK293, MATE transporter, Metformin, PBPK modeling",
author = "May Almukainzi and Ranih Gabr and Ghada Abdelhamid and Raimar L{\"o}benberg",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s40005-017-0307-y",
language = "English",
volume = "47",
pages = "151--161",
journal = "Journal of Pharmaceutical Investigation",
issn = "2093-5552",
publisher = "Springer Netherlands",
number = "2",

}

Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations. / Almukainzi, May; Gabr, Ranih; Abdelhamid, Ghada; Löbenberg, Raimar.

In: Journal of Pharmaceutical Investigation, Vol. 47, No. 2, 01.03.2017, p. 151-161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations

AU - Almukainzi, May

AU - Gabr, Ranih

AU - Abdelhamid, Ghada

AU - Löbenberg, Raimar

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The physiological parameters that describe the reasons behind metformin accumulation in renal failure patients are not fully understood. The effect of high creatinin level in these patients on the elimination of metformin is unknown. The objectives of this work were to (1) evaluate the utility of Physiologically based pharmacokinetic (PBPK) modeling to predict the plasma levels of metformin in healthy and renal impairment individuals (2) identify parameters that explain the observed plasma levels in renal impairment (3) investigate the correlation between creatinine levels and metformin elimination by MATE1 transporter assuming competitive inhibition on this transporter. All simulations were performed using a PBPK approach in GastroPlus™. The simulated data was compared to experimental data in healthy adults and renal failure patients, who received 850 mg metformin HCl. To investigate the effect of creatinin level on the elimination of metformin through MATE1 transporter, 0.35, 0.5, 1, 2, and 5 mg/dl of creatinine on the elimination of 10 µM metformin were investigated in human embryonic kidney (HEK293) and in MATE1 overexpressed HEK293 cell. Our model was able to predict metformin absorption in healthy and renal failure patients. The renal dysfunction model showed that a down-regulation of the MATE1 transporter in kidney and liver was necessary to explain the increase in drug concentration in these patients. However, the accumulation of creatinine in renal impairment patients could not be linked to the MATE1 down-regulation. Understanding the reasons for the increase in metformin blood concentrations can help in reducing the clinical studies and the side effects in these patients.

AB - The physiological parameters that describe the reasons behind metformin accumulation in renal failure patients are not fully understood. The effect of high creatinin level in these patients on the elimination of metformin is unknown. The objectives of this work were to (1) evaluate the utility of Physiologically based pharmacokinetic (PBPK) modeling to predict the plasma levels of metformin in healthy and renal impairment individuals (2) identify parameters that explain the observed plasma levels in renal impairment (3) investigate the correlation between creatinine levels and metformin elimination by MATE1 transporter assuming competitive inhibition on this transporter. All simulations were performed using a PBPK approach in GastroPlus™. The simulated data was compared to experimental data in healthy adults and renal failure patients, who received 850 mg metformin HCl. To investigate the effect of creatinin level on the elimination of metformin through MATE1 transporter, 0.35, 0.5, 1, 2, and 5 mg/dl of creatinine on the elimination of 10 µM metformin were investigated in human embryonic kidney (HEK293) and in MATE1 overexpressed HEK293 cell. Our model was able to predict metformin absorption in healthy and renal failure patients. The renal dysfunction model showed that a down-regulation of the MATE1 transporter in kidney and liver was necessary to explain the increase in drug concentration in these patients. However, the accumulation of creatinine in renal impairment patients could not be linked to the MATE1 down-regulation. Understanding the reasons for the increase in metformin blood concentrations can help in reducing the clinical studies and the side effects in these patients.

KW - Drug simulation

KW - Gastroplus™

KW - HEK293

KW - MATE transporter

KW - Metformin

KW - PBPK modeling

UR - http://www.scopus.com/inward/record.url?scp=85015686324&partnerID=8YFLogxK

U2 - 10.1007/s40005-017-0307-y

DO - 10.1007/s40005-017-0307-y

M3 - Article

AN - SCOPUS:85015686324

VL - 47

SP - 151

EP - 161

JO - Journal of Pharmaceutical Investigation

JF - Journal of Pharmaceutical Investigation

SN - 2093-5552

IS - 2

ER -